Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-11-29 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for November 2016. It references a press release attached as Exhibit 99.1 dated November 28, 2016. The document length is 2640 characters, which is short and primarily serves as a cover report to submit the press release. There is no substantive financial data or detailed report content within this text. According to the rules, such a short document that announces or attaches another report (press release) is classified as a Regulatory Filing (RNS) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-11-29 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of November 2016. It includes a press release as an exhibit and references incorporation by reference into registration statements. The document length is 2646 characters, which is relatively short and primarily serves as an announcement of a press release rather than containing substantive financial data or detailed report content. Form 6-K filings are typically used to furnish reports or documents that foreign private issuers must make public but are not full annual or quarterly reports. Given these characteristics and the nature of the content, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2016-11-29 English
Share Capital Increase - 28 November 2016_EN.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an 'increase in share capital through warrant exercises' and details the issuance of new ordinary shares, the total capital increase amount, and updates to the total number of securities conferring voting rights. This directly relates to changes in the company's capital structure and share count. Based on the provided definitions, the most appropriate classification is 'Share Issue/Capital Change' (SHA). It is not a general financing update (CAP) because it is a specific transaction resulting in new shares, nor is it a transaction in own shares (POS) as it is an issuance via warrant exercise, which is a specific capital event.
2016-11-29 English
Share Capital Increase - 28 november 2016_NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a capital increase resulting from the exercise of warrants ('Galapagos verhoogt kapitaal door uitoefening van warrants'). It details the number of new shares issued and the resulting increase in share capital and total voting rights, referencing Belgian transparency legislation regarding share capital changes. This content directly relates to changes in the company's capital structure and share issuance, matching the definition for 'Capital/Financing Update' (CAP). Although it involves shares, it is not a general share issue announcement (SHA) but a specific financing event via warrant exercise.
2016-11-29 Dutch
Initiation of Phase 1 with CF drug GLPG2737
Regulatory Filings Classification · 95% confidence The document is a press release dated November 28, 2016, announcing a specific corporate event: the initiation of a Phase 1 study for a drug candidate (GLPG2737) and the triggering of a milestone payment from AbbVie. This type of announcement, detailing clinical progress, collaboration milestones, and providing general company/disease background, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement of operational/clinical progress rather than a comprehensive financial report (like 10-K or IR) or a formal notice of a meeting/dividend, it fits best under the 'Earnings Release' category, which often includes key operational highlights preceding a formal earnings report, or 'Regulatory Filings' as a general press release. Given the focus on clinical trial initiation and milestone payments, it functions as an operational update often bundled with or preceding earnings. However, it is not a formal 'Earnings Release' (ER) which typically summarizes P&L/Balance Sheet figures. It is a specific, material announcement. Since it is a formal announcement of material information released to the public, and it doesn't fit the other specific categories (like DIV, CAP, MANG), it defaults to a general regulatory announcement. Given the context of clinical trial updates and collaboration milestones, it is a material event disclosure. In many databases, such press releases are classified as Regulatory Filings (RNS) if they don't fit a more specific operational category like ER (which usually contains summarized financial results). Since this document is a detailed press release announcing a clinical event and partnership update, RNS is the most appropriate general regulatory category.
2016-11-28 English
Start of Fase 1 met CF medicijn GLPG2737
Regulatory Filings Classification · 95% confidence The document is a press release issued by Galapagos NV announcing the start of a Phase 1 clinical trial for a new cystic fibrosis drug (GLPG2737) and the receipt of a milestone payment from AbbVie. It follows the standard format of a corporate press release, including contact information, forward-looking statements, and regulatory disclosures. Since it is an announcement of a specific corporate development (clinical trial progress and milestone payment) rather than a formal financial report, audit, or proxy statement, it falls under the category of general regulatory announcements/filings.
2016-11-28 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.